NasdaqGS:INCYBiotechs
What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders
In the past week, Incyte reported that the European Commission approved Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults who do not respond adequately to or cannot use standard topical therapies, expanding the drug’s European label beyond non-segmental vitiligo.
This decision, backed by strong Phase 3 data showing rapid itch relief and durable skin clearance with a favorable safety profile, coincided with Incyte posting higher quarterly revenue and net income and raising...